Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis

Eveline Y. Wu, MD, MSCR<sup>1</sup> (ORCID 0000-0002-6394-6843), Melissa Oliver, MD, MS<sup>2</sup>, Joshua Scheck, BS<sup>3</sup>, Sivia Lapidus, MD<sup>4</sup>, Ummusen Kaya Akca, MD<sup>5</sup>, Shima Yasin, MD, MSc<sup>6</sup>, Sara M. Stern, MD<sup>7</sup>, Antonella Insalaco, MD<sup>8</sup>, Manuela Pardeo, MD<sup>8</sup>, Gabriele Simonini, MD<sup>9</sup>, Edoardo Marrani, MD<sup>9</sup>, Xing Wang, PhD<sup>10</sup>, Bin Huang, PhD<sup>11</sup>, Leonard K. Kovalick, PNP<sup>1</sup>, Natalie Rosenwasser, MD<sup>3</sup>, Gabriel Casselman, BS<sup>3</sup>, Adriel Liau, BS<sup>3</sup>, Yurong Shao, BS<sup>3</sup>, Claire Yang, BS<sup>3</sup>, Doaa Mosad Mosa, MD<sup>12</sup>, Lori Tucker, MD<sup>13</sup>, Hermann Girschick<sup>14</sup>, Ronald M. Laxer<sup>15</sup>, Jonathan D. Akikusa<sup>16</sup>, Christian Hedrich<sup>17</sup>, Karen Onel, MD<sup>18</sup>, Fatma Dedeoglu, MD<sup>19</sup>, Marinka Twilt, MD<sup>20</sup>, Polly J. Ferguson, MD<sup>6</sup>, Seza Ozen, MD<sup>5</sup>, Yongdong Zhao, MD, PhD<sup>3</sup>. <sup>1</sup>Division of Rheumatology, Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

<sup>2</sup>Division of Pediatric Rheumatology, Indiana University School of Medicine, Indianapolis, IN, **USA** 

<sup>3</sup>Division of Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA, USA

<sup>4</sup>Division of Rheumatology, Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center and Hackensack Meridian School of Medicine, Hackensack, New Jersey, USA

<sup>5</sup>Division of Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey <sup>6</sup>Division of Rheumatology, Allergy and Immunology, Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, USA

<sup>7</sup>Division of Rheumatology, Department of Pediatrics, The University of Utah, Salt Lake City,

Utah, USA

<sup>8</sup>Division of Rheumatology, ERN RITA center, IRCCS Ospedale Pediatrico Bambino Gesù,

Roma, Italy

<sup>9</sup>Rheumatology Unit, ERN ReCONNET center, AOU Meyer Children's Hospital, Florence, Italy

<sup>10</sup>Biostatistics Epidemiology and Analytics in Research, Seattle Children's Research Institute,

Seattle, WA, USA

<sup>11</sup>Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center,

University of Cincinnati College of Medicine, Cincinnati, OH, USA

<sup>12</sup>Rheumatology and Rehabilitation Department, Mansoura University Hospitals, Mansoura

University, Mansoura City, Egypt

<sup>13</sup>Division of Rheumatology, BC Children's Hospital, University of British Columbia,

Vancouver BC, Canada

<sup>14</sup>Department of Pediatrics, Vivantes Clinic Friedrichshain, Germany

<sup>15</sup>The Hospital for Sick Children and the University of Toronto, Toronto, Ontario, Canada

<sup>16</sup>Royal Children's Hospital, Melbourne, Australia

<sup>17</sup>Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, UK

<sup>18</sup>Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, USA

<sup>19</sup>Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA,

**USA** 

<sup>20</sup>Division of Rheumatology, Department of Paeditric, Alberta Children's Hospital, Alberta,

Canada.

## **Corresponding author:**

Yongdong Zhao, MD, PhD

4800 Sand Point Way NE

Seattle, WA 98105

E-mail: ydzhao@uw.edu

ORCiD iD: 0000-0003-3618-1379

Word count (max for original articles is 3,500 words and does not include abstract, references,

tables, and figure legends): 3,475

Abstract (250 Words)

**Introduction:** Prospective comparative effectiveness research in chronic nonbacterial osteomyelitis (CNO) is lacking.

**Objectives:** Study objectives were to: 1) determine the use and safety of each consensus treatment plan (CTP) regimen for CNO, 2) the feasibility of using <u>ch</u>ronic nonbacterial <u>o</u>steomyelitis <u>i</u>nternational <u>registry</u> (CHOIR) data for comparative effectiveness research, and 3) develop and validate a CNO clinical disease activity score (CDAS) using CHOIR.

Methods: Consenting children or young adults with CNO were enrolled into CHOIR.

Demographic, clinical, and imaging data were prospectively collected. The CNO CDAS was developed through a Delphi survey and nominal group technique. External validation surveys were administered to CHOIR participants.

Results: 140 (76%) CHOIR participants enrolled between August 2018 and September 2020 received at least one CTP regimen. Baseline characteristics from the three groups were well matched. Patient pain, patient global assessment, and clinical CNO lesion count were key variables included in the CNO CDAS. The CDAS showed a strong correlation with patient/parent report of difficulty using a limb, back, or jaw and patient/parent report of disease severity, but a weak correlation with patient/parent report of fatigue, sadness, and worry. The change in CDAS was significant in patients reporting disease worsening or improvement. The CDAS significantly decreased after initiating second-line treatments from median 12 (8-15.5) to 5 (3-12). While second-line treatments were well tolerated, psoriasis was the most common adverse event.

**Conclusion:** The CNO CDAS was developed and validated for disease monitoring and assessment of treatment effectiveness. CHOIR provided a comprehensive framework for future comparative effectiveness research.

**Key words:** chronic nonbacterial osteomyelitis, chronic recurrent multifocal osteomyelitis, comparative effectiveness research, clinical disease activity score, consensus treatment plans

## **Key messages:**

- The <u>ch</u>ronic nonbacterial <u>o</u>steomyelitis <u>i</u>nternational <u>registry</u> (CHOIR) provides comprehensive prospective data for comparison of treatment effectiveness
- The clinical disease activity score (CDAS) has content and construct validity to assess CNO

#### Introduction

The treatment of chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO), has been empirical and based on personal experience, expert opinion, and retrospective observational data (1–10). According to a survey of treating pediatric rheumatologists in 2015, 95% reported the use of nonsteroidal antiinflammatory drugs (NSAIDs) as first-line therapy for children with CNO (4). While a majority of children with CNO may initially improve with NSAIDs, approximately 50% will have disease worsening within two years (11). Beyond NSAIDs, there was great variability in selecting second-line treatments which most commonly include methotrexate (67%), tumor necrosis factor inhibitors (TNFi) (65%), and bisphosphonates (46%) (4). Large registries of pediatric patients with CNO such as Eurofever (5) and the German National Pediatric Rheumatology Registry (12) have a limited number of CNO patients who received second-line therapies. A retrospective cohort from three tertiary care centers in the United States (8) reported similar efficacy of TNFi compared to corticosteroids in NSAID-refractory patients with CNO, however, bisphosphonates were not evaluated. Recently, a retrospective chart review from Germany and the UK reported that both TNFi and pamidronate were safe and effective in patients with CNO who failed NSAID treatment (13). There appeared to be a quicker treatment response in patients treated with pamidronate, but more sustained remission in the TNFi group (13). Due to lack of robust evidence from prospective international and multi-ethnic studies, supporting the therapeutic efficacy and safety of any of the second-line treatments, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) CNO working group adopted all three categories of treatments as consensus treatment plans (CTPs) for children with CNO who had an NSAIDrefractory course and/or with active spinal lesions (14). The standard dosing of treatments and

frequency of monitoring were proposed to reduce center-to-center variations for clinical research purpose.

Because of the lack of standardized evaluation tools and sensitive laboratory findings, assessing disease activity in patients with CNO remains a challenge. Historically, pain score has been used as a surrogate for response to therapy, but this approach is limited due to secondary amplified pain syndrome that can occur in CNO (15,16). Magnetic resonance imaging (MRI) can provide detailed information of CNO lesions (17–23) and is used often to evaluate the disease burden for children with CNO at the time of diagnosis. Although regional MRI can be clinically useful, patients can have asymptomatic lesions in other locations. It remains unclear whether all asymptomatic lesions require treatment. Several MRI scoring tools have been developed (18,22,23), but the weighting of lesions at different sites has not been systematically identified. In 2010, Beck et al. (24) developed a core set of CNO outcome variables, PedCNO. Encompassing key variables into a more holistic CNO scale, PedCNO combines patient reported outcomes, laboratory results, and MRI findings. Variables initially thought to be helpful included the erythrocyte sedimentation rate (ESR) and childhood health assessment questionnaire (CHAQ).

In the absence of reliable, prospectively validated and widely accepted disease activity and treatment response criteria, a clinical disease activity assessment tool that is independent of MRI is urgently needed for the assessment of therapies. The <u>ch</u>ronic nonbacterial <u>o</u>steomyelitis international <u>registry</u> (CHOIR) is an international observational longitudinal cohort study of children with CNO that was established by the CARRA CNO workgroup in 2018 (ClinicalTrials.gov Identifier: NCT04725422). The data collection for CHOIR was based on the

7

framework of the CARRA CNO CTPs, and the main target population included children with CNO who failed NSAIDs and/or had high risk lesions (active lesions in vertebral body and/or growth plate) for permanent skeletal damage (14). All the participating sites provided standard clinical care to enrolled patients, and the outcome measurements as well as medication usage were recorded as suggested by the CARRA CNO CTPs (14). The objectives of this study were to: 1) investigate the frequency of use and safety of each CTP regimen, 2) determine the feasibility of using CHOIR data for comparative effectiveness research, and 3) develop and validate a clinical disease activity score (CDAS) for CNO using CHOIR.

#### **Patients and Methods**

#### Patient cohort

Children with clinical diagnosis of CNO were enrolled in CHOIR from 14 sites (8 U.S. sites, 2 Canadian sites, 2 Italian sites, 1 Egyptian site, 1 Turkish site) starting August 1, 2018. Informed consent was obtained for all participants and, additionally, assent was obtained from age-appropriate children. Institutional Board Review approval was obtained at each registry site. Inclusion criteria were 1) age at enrollment \$\mathbb{Q}\$1-years-old, 2) presence of bone edema on short tau inverse recovery (STIR) or T2 fat saturation sequence (e.g. TIRM) on MRI within 12 weeks of enrollment, 3) whole body imaging evaluation either by WBMRI or bone scintigraphy, and 4) a bone biopsy to exclude infection or malignancy unless the bone lesions followed a typical CNO distribution or there was concomitant inflammatory bowel disease (IBD), psoriasis, or palmoplantar pustulosis (PPP). Patients were excluded if they had a current malignancy or infectious osteomyelitis and/or any contraindication for conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), TNFi or bisphosphonates. Between the launching

8

date of CHOIR and September 30, 2020, patients who either had NSAID-refractory disease (defined as failure to improve after 1-3 months regular dosing), and/or active spinal lesions (confirmed by MRI), were enrolled and treated according to one of the CTP regimens at the discretion of the treating physician. Patients were not randomized or masked to their treatment assignment. The CTP choices were 1) csDMARD including but not limited to methotrexate and sulfasalazine; 2) TNFi with or without methotrexate; or 3) bisphosphonates including pamidronate or zoledronic acid. Concurrent use of limited courses of NSAIDs and glucocorticoids was permitted for all regimens (14). After October 1, 2021, we expanded enrollment to all children with CNO regardless of their disease status or need for second-line treatments. Our goal was to use patient questionnaires for the external validation of a newly developed CNO CDAS.

## Development of the CNO CDAS

Our workgroup has followed The OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials) filter 2.1 (25) to develop outcome measurements for CNO (26). A scoping review showed life impact and pathophysiological manifestations (26) to be the main core areas reported in the literature. Using this, CDAS domains were discussed at the CARRA CNO work group monthly meetings and narrowed down to physical exam findings, laboratory findings, patient reported outcomes and physician assessment. At the annual CARRA CNO meeting in 2021, a breakout room session and polling as detailed in the results section were conducted to identify and finalize the core variables for the CNO CDAS.

#### Validation of the CNO CDAS using CHOIR

Surveys included questions measuring patient reported degrees of difficulty using arms/legs/trunk/jaw, fatigue, depression, worry/anxiety, pain, and patient/parent global

assessment using a 0-10 Likert scale. Additional questions (**supplement 1**) assessing self-perceived disease activity (inactive, mildly active, moderately active, or severely active), changes in disease activity compared to the previous visit (improved, worsened, or unchanged), and perceptions of the treatment effectiveness were also administered to participants.

#### Data collection

Demographic and disease-related data were collected at baseline visits and follow-up assessments at 3, 6, 9, 12, 18, and 24 months following enrollment. Unscheduled visits occurred if there was a change or adverse event in the CTP medication. Clinical assessments included: 1) patient pain assessment scored on a 0-10 Likert scale; 2) patient/parent global assessment of disease activity scored on a 0-10 Likert scale; 3) physician global assessment of disease activity scored on a 0-10 Likert scale; 4) total number of clinically active CNO lesions defined as focal tenderness, and/or swelling, and/or warmth in addition to patient's report of pain at a known CNO lesion site (recording sheet is detailed in **supplement 2**); and 5) total CNO lesion count on MRI (14). A CNO CDAS was calculated by summing the patient pain and patient/parent global assessment of disease activity scores and total number of clinically active CNO lesions. Adverse events (AEs) were also collected with special interest on new-onset psoriasis, new-onset autoimmune disease, infection requiring intravenous antibiotics, fracture, and any hospitalization or life-threatening events related to second-line treatments.

#### Statistical analyses

Descriptive statistics were used for demographic and clinical characteristics. For continuous variables, medians and interquartile ranges (IQR) were calculated, and for categorical variables, frequencies and percentages were calculated. Mann–Whitney U tests or Fisher's exact tests were used to assess any significant differences in baseline patient characteristics between

CTPs. Log-transformed linear mixed effect models with random participant intercepts were performed to assess CDAS changes after non-NSAID treatments. Wilcoxon signed rank test with continuity correction was performed to determine the change of the CDAS among reported improved, worsened, and unchanged groups. Spearman's rank correlation test was performed to determine the relationship between the CDAS and reported disease status by patient/families. Participants with missing values or loss to follow-up were excluded from that particular analysis. All computations were performed using R software (version 3.6.1, R Foundation for Statistical Computing, Vienna, Austria). All tests were two-sided, and the results were considered significant if p<0.05.

#### **Results**

## Demographic and clinical data

We identified 140 (78%) out of 179 participants enrolled into CHOIR between August 1, 2018 and September 30, 2020 and treated according to one of the CNO CTP regimens. A total of 39 patients were excluded because of absence of exposure to a second-line treatment. Two received TNFi for pre-existing IBD prior to the diagnosis of CNO. Demographic and clinical features are summarized in **Table 1**. The median age at diagnosis was 9.90 years (IQR 7.99-12.20 years), 55% of the subjects were female, and 84% identified as White Caucasian. There were no significant imbalances in baseline characteristics across three groups including csDMARD-first, TNFi-first (may concomitantly start with methotrexate), and bisphosphonate-first treatment groups (**Table 2**). Specifically, there were no differences between these groups in relation to age, sex, disease duration, interval between diagnosis and treatment start, total MRI lesion count, active spinal lesion, ESR, prior exposure to any csDMARD, and presence of a co-

morbid condition including psoriasis and inflammatory bowel disease (IBD). CRP was significantly different among groups (p=0.001).

## Development of the CNO CDAS

On February 12, 2021, the CARRA CNO workgroup annual meeting was held virtually with 36 participants (comprising 6 family representatives, 24 pediatric rheumatologists, 2 adult rheumatologists, and 4 researchers or research associates). Results from a literature review of existing disease assessment tools including PedCNO (24), CROMRIS (23), RAI-CROMRIS (22), and radiologic index for NBO (RINBO) (18) were presented. The group was divided into six breakout rooms to focus on specific measurements of CNO disease activity from three domains: physical exam findings, labot ratory findings, and patient reported outcomes or physician assessment. The following nine measurements were nominated by the group for consideration: total number of bone lesions with swelling and/or focal tenderness and/or warmth (clinical CNO lesion count), active joint count, ESR, CRP, hemoglobin, alkaline phosphatase, patient/parent global assessment, patient pain, and patient reported outcomes measurement information system (PROMIS) upper and lower extremity function. A ranking poll was carried out, and the three variables ranked the highest were patient pain, patient global assessment, and clinical CNO lesion count. Therefore, the CNO CDAS is calculated as a sum score encompassing these three variables.

#### Validation of the CNO CDAS

From November 2021, external validation surveys to patients/parents and physicians were administered within CHOIR. We included children with a clinical diagnosis of CNO made by treating physicians who completed the survey and had available core variable values at the baseline and/or follow up visits. Standard of care including NSAIDs and/or second-line

treatments were carried out. Degrees of difficulty of using limb/trunk/jaw, fatigue, depression, worry, self-perceived disease activity, improvement/worsening in disease activity, and perception of treatment effectiveness were reported. The construct validity of the CDAS was determined for three aspects and showed a significant correlation with patient/parent reported difficulty with using an affected body part, fatigue, sadness, worry, and physician global assessment (Table 3). There was a strong correlation between the CDAS and reported difficulty with using a limb, the back, or jaw (rho=0.65, p<0.001), with a weak correlation between the CDAS and reported fatigue, sadness, and worry (rho=0.24-0.39, p<0.001). Furthermore, the CDAS was significantly correlated with patient reported inactive disease, mildly active disease, moderately active disease, and severely active disease (rho=0.75, p<0.001) (**Figure 1**). It was noted that 25% of subjects had CDAS value of two or greater during inactive disease. The change of CDAS was significant in patients reporting disease worsening or improvement (p<0.001) while not significant in those reporting unchanged disease (p=0.526) (**Table 4**). The median change in the CDAS in patients reporting a significant improvement after treatment initiation was -2.5 (-5.8-(-0.3)). The CDAS increase in patients reporting significant worsening was 11 (4-12) (supplement 3). The CDAS significantly decreased after the initiation of secondline treatments from 12 (8-15.5) to 5 (3-12) (p=0.002) (**Table 5**).

#### Response to CTP options

Of the 140 participants included in this study, 101 participants had complete data and 6-month follow-up. Due to the sequential exposure or concurrent administration of more than one CTP medication from baseline to follow-up, responses in clinical assessments were analyzed collectively. Treatment with a csDMARD, TNF inhibitor, and/or bisphosphonate resulted in significant improvement in clinical response (**Table 5**). Compared to baseline, patient pain (4 [1-

8] versus 2 [0-7]) did not significantly differ, however, patient/parent global assessment of disease activity (6 [3-8] versus 2 [1-5]) and total number of clinically active lesions (1 [0-2] versus 0 [0-1]) all improved with second-line treatment (all p<0.05).

### Adverse events to CTP options

The total patient years for each CTP regimen were 351 for csDMARD, 294 for TNF inhibitors, and 89 for bisphosphonates. The most common adverse event was the development of psoriasis. There were 13 new cases of psoriasis, including two cases (among a total of 45 patient years) who developed psoriasis while taking leflunomide alone, seven cases (among a total of 114 patient years) while taking adalimumab, and four cases (among a total of 77 patient years) while taking infliximab. Two patients developed alopecia, one during treatment with leflunomide and the other with adalimumab. Two patients developed inflammatory arthritis, including one receiving a combination of pamidronate and methotrexate and one receiving methotrexate monotherapy. There was one patient each who developed a vertebral body compression fracture while on methotrexate, type 1 diabetes mellitus while on methotrexate, herpes zoster while on infliximab, and bacteremia requiring intravenous antibiotics while on infliximab and subtherapeutic dose of methotrexate. Among reasons to discontinue a CTP medication, only two of 205 occasions were due to adverse events. Both patients discontinued infliximab due to severe psoriasis.

#### **Discussion**

This pilot study demonstrated that the CARRA CNO CTPs are feasible and were used successfully across sites internationally within the CHOIR framework. The lack of significant differences in baseline patient characteristics between CTPs supports the diversity in prescribing

patterns and allows the application of causal inference statistics to compare the effectiveness of non-NSAIDs treatments without randomization. Due to the rarity of the disease and the challenge of randomizing patients, and blinding patients and physicians from the treatments, large-scale randomized control trials have not been performed in children with CNO yet.

Observational registries such as Eurofever (5), the German National Pediatric Rheumatology Registry (12), and now CHOIR can provide real world data to substantiate decision making for physicians and families. The use of biologics is limited in the two other registries but is enriched in CHOIR. A comparison of adalimumab and bisphosphonate has been proposed by a group of experts as a needed clinical trial (27). Recent retrospective cohort data suggest safety and efficacy of both, but higher relapse rates in patients treated with pamidronate (13). However, patients were not randomized and the cohort treated initially with TNFi exhibited higher inflammatory parameters and more bone lesions. Within the pamidronate group, failure to respond was associated with female gender, elevated systemic inflammatory parameters and increased numbers of bone lesions.

Results from this pilot study suggest that the CHOIR framework can be used to compare the effectiveness and safety among commonly prescribed medications. Notably, the distribution of characteristics of children with CNO receiving TNFi and those receiving bisphosphonates was comparable and balanced across groups, suggesting it is feasible to compare the effectiveness of these two medications within CHOIR. In a relatively large proportion of patients, there was a sequential use of csDMARD prior to use of TNFi or bisphosphonates, making it difficult to determine the effectiveness across all second-line treatments in CHOIR. However, retrospective studies (8,11) and surveys from families (28) suggest csDMARDs are less effective than TNFi and bisphosphonates for the treatment of CNO. Thus, a future main goal will be to focus on two

second-line treatments used for CNO, TNFi and bisphosphonates, to provide more robust and accurate information as to their comparative safety and efficacy.

Prior to our study, there has not been any validated, standardized outcome assessment in CNO. The CNO CDAS has been validated through external questionnaires to patients/parents and physicians. Changes in CNO CDAS scores after second-line treatments were significant, while patient pain as an individual component did not reach significance. This may have been caused by the relatively high proportion of pain amplification in CNO (15,16), and highlights the comprehensive and robust nature of the CNO CDAS. The strong correlation coefficient between functional limitations with impaired use of arms/legs/back/jaw and physician global assessment with the CNO CDAS showed convergent validity, whereas the significant weak correlation between fatigue, depression, and worry and the CNO CDAS showed divergent validity. Furthermore, the excellent correlation of self-reported disease activity by patient/parent and the CNO CDAS established the capacity of the CNO CDAS as a disease severity assessment for future studies. While future study is needed to determine whether the CNO CDAS is a helpful measure that can be used not only in clinical research for CNO, but also in clinical practice, results promise potential for the CDAS score as a feasible and robust clinical-based disease activity assessment tool that can be calculated without requiring imaging data.

Safety monitoring has revealed psoriasis as the most common associated event within CHOIR, occurring in patients treated with leflunomide and monoclonal TNFi. Because psoriasis is highly associated with CNO, it is possible that a subset of patients developed psoriasis as part of natural history regardless of their exposure to these two types of medications. Nevertheless, it has been established that TNFi-associated psoriasis occurs in children with CNO (29–31), and the risk of paradoxical psoriasis after TNFi exposure is higher in children with CNO than in

children with juvenile idiopathic arthritis or IBD (30). Concomitant use of methotrexate may decrease the risk of developing psoriasis (31,32). This is the first report of psoriasis occurring in a CNO patient treated with leflunomide, but further data is needed to determine if this is a new association. Other adverse events including the new onset of immune-mediated conditions and bacteremia were rare. There was no adverse event reported while patients received pamidronate suggesting its safety in children with CNO as previously reported (33). Overall, our data suggest that these medications have a favorable safety profile.

While providing promising data supporting the use of CHOIR and the new CDAS score to compare treatment outcomes in CNO, this study has several limitations. First, the observational nature of CHOIR does not allow randomization therefore the selection of treatments may be subject to the individual provider's bias. However, the distribution of confounding factors is matched across different second-line treatments, which makes it possible to infer the relative effectiveness. Second, the follow up time is only two years for the inception cohort. Previous studies suggested that the median duration to a first disease flare ranges around 29 months in children treated with NSAIDs (11). However, we intend to continue data collection for 10 years or until patients transition to adult care. Third, missing data components of the CDAS from the visits prior to the validation of the CDAS did not allow for the comparison of treatment effectiveness using the CDAS. Future studies in CHOIR will include all of the components of the CDAS and lead to a clinical-score based assessment of disease activity and treatment response. Lastly, the MRI component of CHOIR has been collected based on site report of the total number of MRI lesions. A centralized imaging scoring will be needed to ensure that the readings of MRIs are reproducible.

Overall, this pilot study provided knowledge and experience that can be applied towards refining the CHOIR framework. Future efforts include building a larger cohort with more long-term data and clinical assessments to optimize analysis of the relative effectiveness of each CTP treatment option using the CDAS. We ultimately hope that results from larger-scale comparative effectiveness studies using this registry-based cohort can inform more robust evidence-based treatment guidelines and improve outcomes for this rare rheumatic disease.

#### **Conclusions**

The CNO CDAS was developed and validated for disease monitoring and assessment of treatment effectiveness for children with CNO. CHOIR provides a feasible and comprehensive framework for comparative effectiveness research in the future.

Funding: The CRMO Warriors Guild of the Seattle Children's Foundation supported the data collection at Seattle Children's Hospital, coordination of all participating sites, and the statistical analysis. Dr. Zhao's work was also supported by the Rheumatology Research Foundation, ACR, EULAR, and the Washington Research Foundation. Dr. Wu's work was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2TR002490 and through generous donations from The Kioti Tractor Company, The Kim family, and The Smith family. Dr. Oliver was supported by a CARRA-Arthritis Foundation small grant.

**Conflict of interest:** Dr. Wu receives advisory board fees from Pharming Healthcare, Inc. and research funding from Bristol-Myers Squibb, Janssen, and Enzyvant. Dr. Oliver served as a committee member on ACR RheumPAC. Dr. Stern received a Sjogren's Foundation Grant and

18

served in the Arthritis Foundation Medical Advisory for Idaho and Utah. Dr. Tucker served as a Board member of the Cassie & Friends Society. Dr. Ozen received consulting fees from Novartis and SOBI. Dr. Zhao received research funding from Bristol-Myers Squibb, royalties from UptoDate and consulting fees from Novartis in 2020. Dr. Ferguson is supported by the Marjorie K. Lamb Professorship, serves on the American Board of Pediatrics Pediatric Rheumatology Subboard, has funding from the NIH (NINDS and NICHD) and received a consulting fee from Novartis in 2020. Dr. Dedeoglu receives royalties from UptoDate and received a consulting fee from Novartis in 2020. Dr. Twilt serves on the TMJaw board and has received funding support from CARRA, the Arthritis Society, and CIHR. Dr. Laxer receives royalties from UptoDate, consulting fees from Sobi, Novartis, Eli Lilly, Sanofi, Sobi, serves on the Education Committee of the ACR, and on the Board of the CRMO Foundation, CACP Foundation and Canadian Autoinflammatory Network. Dr. Akikusa received honoraria from Novartis in 2022.

### Acknowledgements

The authors thank the CHOIR participants, research assistants and volunteers at all sites including Teresa Dickson, Corinne Lawler, Sumaya Aden, Thuan Bui, Kyra Shelton, Esha Mahal, Annie Xu, Kellen James, Shayla Nguyen, Zheng Xu, Ava Klein, Chessie Snider, Mabel Ho, Trang Pham, Anna Saack, Paige Trunnell, Emily Deng, Ana Park, Cailey Karshmer, Emma Leisinger, Mary Ellen Riordan, and Justine Griswold. We appreciate the help from Ingrid Goh, Mariana Correia Marques, and Min-Lee Chang for the testing of the registry database and the training material. In addition to the authors, the following CARRA CNO workgroup members participated in the February 2021 meeting: Ingrid Goh, Brian Nolan, Tzielan Lee, Annette Jansson, Aleksander Lenert, Lina Jaberi, David Cabral, Lauren Potts, Arielle Hay, Karine

Toupin-April, Akaluck Thatayatikom, Ingram Chang, Piya Lahiry, Anja Schnabel, Mikhail Kostik, Nathan Rogers, Achille Marino, Dita Cebecauerova, Phillip Mease, Lindsey Bergstrom, Suzanne Li, Deborah McCurdy, Alex Theos, Matthew Hollander, Samira Nazzar, Farzana Nuruzzaman, Beverley Shea, and Chris Obrien.

#### References

- Zhao Y, Laxer R., Ferguson P. Treatment Advances in Chronic Non-Bacterial
   Osteomyelitis and Other Autoinflammatory Bone Conditions. Curr Treat Options
   Rheumatol. 2017;3(1):17-32. DOI 10.1007/s40674-017-0058-y.
- Zhao Y, Ferguson PJ. Chronic Nonbacterial Osteomyelitis and Chronic Recurrent Multifocal Osteomyelitis in Children. Pediatr Clin North Am. 2018;65(4):783–800.
- Hedrich CM, Hofmann SR, Pablik J, Morbach H, Girschick HJ. Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO).
   Pediatr Rheumatol Online J. 2013;11(1):47.
- Zhao Y, Dedeoglu F, Ferguson P, Lapidus S, Laxer R, Li S. Physicians' Perspectives on the Diagnosis and Treatment of Chronic Nonbacterial Osteomyelitis. Int J Rheumatol. 2017;DOI: 10.1155/2017/7694942.
- 5. Girschick H, Finetti M, Orlando F, Schalm S, Insalaco A, Ganser G, et al. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology. 2018;57(8):1504.
- 6. Wipff J, Costantino F, Lemelle I, Pajot C, Duquesne A, Lorrot M, et al. A large national cohort of French patients with chronic recurrent multifocal osteitis. Arthritis Rheumatol. 2015 Apr;67(4):1128–37.
- 7. Jansson A, Renner ED, Ramser J, Mayer A, Haban M, Meindl A, et al. Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology (Oxford). 2007 Jan;46(1):154–60.
- 8. Borzutzky A, Stern S, Reiff A, Zurakowski D, Steinberg EA, Dedeoglu F, et al. Pediatric Chronic Nonbacterial Osteomyelitis. Pediatrics. 2012 Oct 15;130(5):e1190-7.

- 9. Bhat CS, Roderick M, Sen ES, Finn A, Ramanan A V. Efficacy of pamidronate in children with chronic non-bacterial osteitis using whole body MRI as a marker of disease activity. Pediatr Rheumatol. 2019;17(1):1–5.
- Gaal A, Basiaga ML, Zhao Y, Egbert M. Pediatric chronic nonbacterial osteomyelitis of the mandible: Seattle Children's hospital 22-patient experience. Pediatr Rheumatol. 2020;18(1):1–10.
- Schnabel A, Range U, Hahn G, Berner R, Hedrich CM. Treatment Response and Longterm Outcomes in Children with Chronic Nonbacterial Osteomyelitis. J Rheumatol. 2017;44(7):1058–65.
- 12. Reiser C, Klotsche J, Hospach A, Berendes R, Schnabel A, Jansson AF, et al. First-year follow-up of children with chronic nonbacterial osteomyelitis-an analysis of the German National Pediatric Rheumatologic Database from 2009 to 2018. Arthritis Res Ther. 2021 Nov;23(1):281.
- 13. Schnabel A, Nashawi M, Anderson C, Felsenstein S, Lamoudi M, Poole-Cowley J, et al. TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? Results of an international retrospective multicenter study. Clin Immunol. 2022;238(April):109018.
- 14. Zhao Y, Wu EY, Oliver MS, Cooper AM, Basiaga ML, Vora SS, Lee TC, Fox E, Amarilyo G, Stern SM, Dvergsten JA, Haines KA, Rouster-Stevens KA, Onel KB, Cherian J, Hausmann JS, Miettunen P, Cellucci T, Nuruzzaman F, Taneja A, Barron KS, Hollander MC, Lapidus S, Li SC, Ozen S, Girschick H, Laxer RM, Dedeoglu F, et al. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Anti-Inflammatory Drugs and/or with Active Spinal Lesions. Arthritis Care Res (Hoboken). 2018;70(8):1228–37.

- 15. Voit AM, Arnoldi AP, Douis H, Bleisteiner F, Jansson MK, Reiser MF, et al. Whole-body magnetic resonance imaging in chronic recurrent multifocal osteomyelitis: Clinical longterm assessment may underestimate activity. J Rheumatol. 2015;42(8):1455–62.
- 16. O'Leary D, Wilson AG, MacDermott EJ, Lowry C, Killeen OG. Variability in phenotype and response to treatment in chronic nonbacterial osteomyelitis; the Irish experience of a national cohort. Pediatr Rheumatol. 2021;19(1):1–8.
- 17. Guérin-Pfyffer S, Guillaume-Czitrom S, Tammam S, Koné-Paut I. Evaluation of chronic recurrent multifocal osteitis in children by whole-body magnetic resonance imaging. Joint Bone Spine. 2012;79(6):616–20.
- 18. Arnoldi AP, Schlett CL, Douis H, Geyer LL, Voit AM, Bleisteiner F, et al. Whole-body MRI in patients with Non-bacterial Osteitis: Radiological findings and correlation with clinical data. Eur Radiol. 2017;27(6):2391–9.
- von Kalle T, Heim N, Hospach T, Winkler P, Stuber T. Typical Patterns of Bone Involvement in Whole-Body MRI of Patients with Chronic Recurrent Multifocal Osteomyelitis (CRMO). Fortschr Röntgenstr. 2013;185:655–61.
- Iyer RS, Thapa MM, Chew FS. Chronic recurrent multifocal osteomyelitis: review. AJR
   Am J Roentgenol. 2011 Jun;196(6 Suppl):S87-91.
- 21. Sato TS, Watal P, Ferguson PJ. Imaging mimics of chronic recurrent multifocal osteomyelitis: avoiding pitfalls in a diagnosis of exclusion. Pediatr Radiol. 2020;50(1):124–36.
- 22. Capponi M, Pires Marafon D, Rivosecchi F, Zhao Y, Pardeo M, Messia V, et al.

  Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis. Pediatr Rheumatol Online J. 2021

- Aug;19(1):123.
- 23. Zhao Y, Sato TS, Nielsen SM, Beer M, Huang M, Iyer S, et al. Development of CROMRIS (ChRonic nonbacterial Osteomyelitis MRI Scoring) Tool and Evaluation of its Interrater Reliability. J Rheumatol. 2019;Oct 1. pii: jrheum.190186. doi: 10.3899/jrheum.190.
- 24. Beck C, Morbach H, Beer M, Stenzel M, Tappe D, Gattenlöhner S, et al. Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment. Arthritis Res Ther. 2010 Jan;12(2):R74.
- 25. Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, et al.
  OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome
  Measurement in Health Intervention Studies. J Rheumatol. 2019 Aug;46(8):1021–7.
- Oliver M, Jayatilleke A, Wu E, Nuruzzaman F, Aguiar C, Lenert A, et al. Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Semin Arthritis Rheum [Internet]. 2021;51(4):957–61. Available from: https://doi.org/10.1016/j.semarthrit.2021.05.015
- 27. Ramanan A V., Hampson L V., Lythgoe H, Jones AP, Hardwick B, Hind H, et al.

  Defining consensus opinion to develop randomised controlled trials in rare diseases using
  Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for
  children with CNO/CRMO. PLoS One. 2019;14(6):1–16.
- 28. Oliver M, Lee TC, Halpern-Felsher B, Murray E, Schwartz R, Zhao Y. Disease burden and social impact of pediatric chronic nonbacterial osteomyelitis from the patient and family perspective. Pediatr Rheumatol. 2018;16(1):1–8.

- 29. Campbell JA, Kodama SS, Gupta D, Zhao Y. Case series of psoriasis associated with tumor necrosis factor-α inhibitors in children with chronic recurrent multifocal osteomyelitis. JAAD Case Reports. 2018;4(8):767–71.
- 30. Buckley LH, Xiao R, Perman MJ, Grossman AB, Weiss PF. Psoriasis Associated with Tumor Necrosis Factor-Alpha Inhibitors in Children with Inflammatory Diseases.

  Arthritis Care Res (Hoboken). 2019;Oct 23. doi: 10.1002/acr.24100.
- 31. Kodama S, Gupta D, Sullivan E, Rosenwasser N, Zhao Y. Paradoxical psoriasis after exposure to tumour necrosis factor inhibitors in children: a retrospective cohort study. The British journal of dermatology. England; 2022.
- 32. Zhao Y, Sullivan E, Son MB, Beukelman T. Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA. Ann Rheum Dis. 2022 May;81(5):662–5.
- Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig [Internet].
   2019;40(2):20190021. Available from: https://doi.org/10.1515/hmbci-2019-0021

Table 1. Demographics of the CHOIR inception cohort between 2018 and 2020

Variables	Median[IQR] or		
variables	frequency (%)		
	n=140		
Age at onset, yr (n=133)	9.04 [7.08, 10.92]		
Age at diagnosis, yr (n=138)	9.90 [7.99, 12.20]		
Disease duration since diagnosis, month (n=133)	26.92 [9.48, 51.02]		
Age at enrollment, yr	11.97 [9.65, 14.31]		
Female	77 (55.0)		
Race, White	118 (84.3)		
Coexisting conditions			
Psoriasis	8 (5.7)		
IBD (Crohn's, UC)	10 (7.1)		
Arthritis (JIA, ERA)	10 (7.1)		
Family history (1st degree relatives)			
Psoriasis	14 (10.0)		
IBD (Crohn's, UC)	10 (7.1)		
Arthritis (JIA, ERA)	1 (0.7)		
Family history (2nd degree relatives)			
Psoriasis	17 (12.1)		
IBD (Crohn's, UC)	11 (7.9)		
Arthritis (JIA, ERA)	4 (2.9)		
Bone biopsy ever obtained	87 (62.6)		
Active spinal lesion on MRI within 12 weeks	17 /68 (25.0)		
Active lesion present on MRI within 12 weeks	91/102 (89.0)		
Failed NSAIDs	115 (82.1)		

ERA: enthesitis-related arthritis, IBD: inflammatory bowel disease, IQR: interquartile range, JIA: juvenile idiopathic arthritis, MRI: magnetic resonance imaging, NSAID: non-steroidal anti-inflammatory drug, UC: ulcerative colitis,

Table 2. Comparison of pre-treatment characteristics among the three CNO CTP regimens

Washington (IOD) as for an array (IV)	csDMARD-first	TNFi-first	Bisphosphonate-first	p-value
Variables, median (IQR) or frequency (%)	n=82	n=31	n=25	
Age at onset, yr (n=133)	9.08 [7.00, 11.04]	8.73 [7.14, 9.55]	9.54 [7.60, 11.54]	0.435
Age at diagnosis, yr	9.87 [7.70, 12.10]	9.43 [8.62, 11.38]	10.57 [8.79, 13.01]	0.676
Age at enrollment, yr	11.78 [9.38, 14.18]	12.06 [9.79, 14.18]	12.51 [10.26, 14.66]	0.588
Female	41 (50.0)	17 (54.8)	18 (72.0)	0.153
Disease duration, yr (n=133)	2.23 [0.98, 3.97]	2.95 [0.68, 5.29]	1.19 [0.55, 3.40]	0.362
Interval between diagnosis and initiation of treatment (yr)	0.12 [0.00, 0.54]	0.35 [0.05, 1.23]	0.13 [0.07, 0.41]	0.108
Clinical CNO lesion count* (n=61)	1.00 [0.00, 2.75]	1.50 [0.00, 3.50]	1.00 [0.00, 2.00]	0.861
Total MRI lesion count* (n=43)	5.00 [2.75, 8.25]	4.50 [2.00, 5.00]	4.00 [3.00, 9.00]	0.909
Active spinal lesion*	6/25 (24.0)	4/12 (33.3)	8/17 (47.1)	0.299
C-Reactive Protein (mg/dL) (median [IQR]) (n=91)	0.80 [0.80, 0.80]	0.80 [0.80, 1.94]	0.80 [0.80, 13.94]	0.001
ESR (median [IQR]) (n=100)	9.00 [5.00, 16.00]	11.00 [7.00, 29.50]	15.00 [8.00, 36.00]	0.141
Presence of psoriasis	3 (3.7)	2 (6.5)	1 (4.0)	0.842
Presence of IBD	4 (4.9)	4 (12.9)	1 (4.0)	0.304

Two patients with unclear dates of initiation of medication or diagnosis of CNO were excluded. \*Timing was within 90 days prior to initiation of medications, if there are multiple scores, the closest one to the initiation of medications was used. DMARD: disease modifying anti-rheumatic drug, IBD: inflammatory bowel disease, IQR: interquartile range, MRI: magnetic resonance imaging

Table 3. CDAS convergent and divergent validation using patient reported outcome

Variables	Estimates	CI	Correlation rho	P-value
Physician assessment (0-10) (n=809)	0.3	0.27 - 0.33	0.76	< 0.001
Difficulty to use limb/back/jaw (n=209)	0.29	0.24 - 0.35	0.66	< 0.001
Fatigue (n=208)	0.15	0.10 - 0.20	0.37	< 0.001
Sadness (n=207)	0.17	0.09 - 0.24	0.35	< 0.001
Worry (n=207)	0.13	0.07 - 0.19	0.24	0.002

CI: confidence interval. Data for Physician assessment were between 8/2018 and 9/2022 whereas data for other parameters were only available from 11/2021.

29

Table 4. Correlation of CDAS changes with patient reported disease status change

Grouping	n	Median [IQR]	P-value*
Delta CDAS in the reported worsening group	16	9.00[5.25,11.25]	< 0.001
Delta CDAS in the reported improved group	64	- 3.50[-6.00, -0.75]	< 0.001
Delta CDAS in the reported unchanged group	8	- 1.00[-3.00, 0.50]	0.526

<sup>\*</sup>Wilcoxon signed rank test with continuity correction comparing to zero


30

Table 5. CDAS changes after second-line treatments

Variables	Before	After	p-value
Patient pain VAS (n=101)	4.00 [1.00, 7.50]	2.00 [0.00, 7.00]	0.155
Patient/parent global assessment VAS (n=53)	6.00 [3.00, 8.00]	2.00 [1.00, 5.00]	< 0.001
Total number of clinically active lesions (n=126)	1.00 [0.00, 2.00]	0.00 [0.00, 1.00]	< 0.001
CNO CDAS (n=41)	12.00 [8.00, 15.50]	5.00 [3.00, 12.00]	0.002


VAS: visual analogue scale, CDAS: clinical disease activity score

Figure 1. Plot of CDAS by the patient-reported disease severity. Spearman's rank correlation showed rho =0.75, p<0.001.



# Supplement 1. External validation surveys Patient version (Age 8 and above):


- 1. How would you rate your function using the rating scale as provided.
- □Current ease to use your body including arms, legs, back and jaw? Rate the most problematic site from 0 to 10.



No difficulty

Extreme difficulty


□Please rate your current pain level from 0 to 10?



No pain

Extremely painful


□Please rate your current fatigue from 0 to 10?



No fatigue

Extreme fatigue


□How would you rate your current mood from 0 to 10?



Normal

Extremely sad

□ Please rate your current feelings of worry from 0 to 10?



No worry

Extremely worried


_How wou	id you rate your current CNO disease activity from 0 to 10?
$\bigcirc$	
•	1 2 3 4 5 6 7 8 9 10
None	Very bad
2. How wo	uld you evaluate the current state of your illness? Active disease Inactive disease
3. If there i	s active disease, please provide an estimation of the overall level of disease activity.  Mild disease activity  Moderate disease activity  High/severe disease activity
4. How wo	uld you evaluate the changes of your illness since last visit?
	Not applicable (1st visit)
	Much worsened
	Slightly worsened
	Stable/unchanged
	Slightly improved
	Much improved

## Proxy version (age 7 and below):

Moderate disease activity

High/severe disease activity

#### Patient proxy questionnaire for external validation (Age <8 years)



<b>1</b> . I	How would you evaluate the changes of your child's illness since last visit?
	Not applicable (1st visit)
	Much worsened
	Slightly worsened
	Stable/unchanged
	Slightly improved
	Much improved

# Supplement 2. Physical exam recording sheet for children with CNO Please mark with 'X' physical exam findings:

Lower spine (Back)

	R	IGHT				L	LEFT		
Pain complaint	Heat/Warmt		Tenderness	SITE	Pain Heat/Warmt complaint			Tenderness	
				Skull (Head)					
				Maxilla (Head)					
				Mandible (Face bone)					
				Clavicle (Collar bone)					
				Rib(s)					
				Scapula					
				Proximal Humerus					
				Mid- Humerus					
				Distal Humerus					
				Proximal Forearm					
				Mid- Forearm					
				Distal Forearm					
				Hand					
				Sacroiliac joint					
				Pelvis- ilium					
				Pelvis- ischium					
				Proximal Femur					
				Mid- Femur					
				Distal Femur					
				Patella					
				Proximal Lower leg					
				Mid- Lower leg					
				Distal Lower leg					
				Hindfoot					
				Midfoot					
				Forefoot					
	SITE		Heat/Warmth		ng 1	enderness			
Sternum (che	st bone)								
Neck									
Upper spine (I									
Mid-spine (Ba	ck)								

There are two options for each blank: "present" or "absent". Default choice will be "absent"

38

Supplement 3. The changes of CDAS from groups who reported significantly improved or significantly worsened\*

	n	absolute value, median [IQR]
CDAS changes in patients who reported significant improvement	22	-2.5[-5.8,-0.3]
CDAS changes in patients who reported significant worsening	5	11[4,12]
*CDAC abances are calculated using the visit with non-arted significant immediate		manina tha adiacant mast misit (s. 2)

<sup>\*</sup>CDAS changes are calculated using the visit with reported significant improvement/worsening - the adjacent past visit (>30day). IQR: interquartile range.